
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is viewed positively because its high-margin royalty model keeps producing earnings beats, with Q3/26 revenue of $78.7MM and adjusted core EPS of $2.67 both topping estimates, while 2026 EPS guidance was raised to $9.50–$9.75 per share. Its investment case is further strengthened by the XOMA acquisition, which added 100+ programs, several commercial assets, and meaningful cost synergies, with management expecting operating expense to fall from about $25MM+ to just under $5MM and incremental EPS contribution in 2026 and 2027. The outlook is also supported by a deep catalyst pipeline, including priority review for Qtorin rapamycin with a Feb. 28, 2027 PDUFA date, strong Filspari royalty momentum, and more than $500MM in deployable capital to pursue accretive royalty deals.
Bears say
Ligand Pharmaceuticals is viewed negatively because its earnings are heavily exposed to royalty streams that could weaken if commercial products face stronger competition or slower sales, leaving little cash flow after Yr 10 in a downside case. Its dependence on Captisol adds another concentration risk, while manufacturing, IP, and strategic acquisition/integration failures could directly impair operations and shareholder value. The company’s pipeline and newly commercialized drugs also carry elevated clinical, regulatory, reimbursement, and patent risks, and if acquisitions or financing do not align with management’s targets, the stock could face additional downside.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ligand Pharmaceuticals (LGND) Forecast
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares